Session » Health Services Research - Poster III

Date: Tuesday, November 15, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2240

A Descriptive Analysis of Real-World Treatment Patterns in a Turkish Rheumatology Population That Continued Innovator Infliximab (Remicade) Therapy or Switched to Biosimilar Infliximab

9:00AM-11:00AM: Abstract Number: 2250

A Real World View of Rheumatoid Arthritis Patients Treated with Advanced Therapies: Comparing Patient Profiles and Outcomes

9:00AM-11:00AM: Abstract Number: 2232

Above-Label Dosing with Biologics in Treatment-NaïVe and Treatment-Experienced Patients with Moderate-to-Severe Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2237

Biologic DMARD Use Among U.S. Patients in an Online Rheumatoid Arthritis Community

9:00AM-11:00AM: Abstract Number: 2231

Change in Health Care Utilization after Etanercept Initiation in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2242

Comparison of Assessment and Management of RA and Other Rheumatic Diseases By Rheumatologists in Private Practices or an Academic Medical Center

9:00AM-11:00AM: Abstract Number: 2249

Comparison of Discontinuation Rates Among Patients with RA Initiating Biologics

9:00AM-11:00AM: Abstract Number: 2229

Economic Burden of Rheumatoid Arthritis Is Higher for ACPA-Positive Patients

9:00AM-11:00AM: Abstract Number: 2234

Economic Impact of Above-Label Dosing with Biologics in Patients with Moderate-to-Severe Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2236

Effects of Repository Corticotropin Injection on Medication Use in Patients with Rheumatologic Conditions: A Claims Data Study

9:00AM-11:00AM: Abstract Number: 2252

Estimated Cost of SLE Hospitalizations

9:00AM-11:00AM: Abstract Number: 2246

Glucocorticoids in Early Rheumatoid Arthritis Management, Friend or Foe?

9:00AM-11:00AM: Abstract Number: 2241

Health Economics of Uncontrolled Gout in the United States: A Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 2245

Injectable Corticosteroid Use in Musculoskeletal Care Specialties

9:00AM-11:00AM: Abstract Number: 2230

Models Using Claims-Based Administrative Data Are Poor Predictors of Rheumatoid Arthritis Disease Activity in VA Rheumatoid Arthritis (VARA) Patients

9:00AM-11:00AM: Abstract Number: 2254

Patient Adherence with Biologic Therapy in Rheumatoid Arthritis: A Real-World Review of Compliance

9:00AM-11:00AM: Abstract Number: 2239

Patterns of Abatacept Utilization in Patients with Rheumatoid Arthritis. Have the Baseline Characteristics of These Patients Changed over Time?

9:00AM-11:00AM: Abstract Number: 2233

Predictors of Adherence and Costs in First and Second Years after Biologic Initiation in Patients with Rheumatoid Arthritis (RA)

9:00AM-11:00AM: Abstract Number: 2238

RA Medication Preferences Among U.S. Patients in an Online Rheumatoid Arthritis Community

9:00AM-11:00AM: Abstract Number: 2247

REAL-Life Cost of UK Healthcare Resource for Patients with Rheumatoid Arthritis, Comparing High and Low/Remission Disease States

9:00AM-11:00AM: Abstract Number: 2228

Real-World Cost of Treating Inadequate Responders to Anti-Tumor Necrosis Factor Therapy

9:00AM-11:00AM: Abstract Number: 2251

Secukinumab Vs Adalimumab for the Treatment of Ankylosing Spondylitis: A Cost per Responder Analysis at 52 Weeks from the US Perspective

9:00AM-11:00AM: Abstract Number: 2227

Sustained Remission and Relapse Rate after Non-Conventional DMARD Withdrawal in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2248

The “Financial Toxicity” of Therapy in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2243

The Paucity of the Evidence Base for American College of Rheumatology Practice Guidelines

9:00AM-11:00AM: Abstract Number: 2253

Treatment Persistence with Subcutaneous TNF-Alpha Inhibitors in France

9:00AM-11:00AM: Abstract Number: 2235

Utilization of Ambulatory Physician Encounters, Emergency Room Visits and Hospitalizations By RA Patients: A 13 Year Population Health Study

9:00AM-11:00AM: Abstract Number: 2244

Utilization Patterns of Subcutaneously Administered Biologic Medications within a Sample of Rheumatoid Arthritis Patients

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].